IGI Logo

Looking ahead to ADC

Suven Pharma’s (SUVENPHA IN) recent analyst day at Hyderabad offered insight into the company’s growth strategy and business segments. Senior management outlined their vision to achieve USD 1.0bn revenue by FY30, with contract development and manufacturing organization (CDMO) likely to contribute 80% of revenue. Dr Naresh Jain, head of the newly acquired NJ Bio, provided an in-depth analysis of the antibody-drug conjugates (ADC) industry and the company’s competitive advantage in this space. The analyst day also included site tours of Casper Pharma’s oral solid dosage (OSD) facility, the ADC site at Nacharam(Huderabad, Telangana), and an R&D unit at Genome Valley (Huderabad, Telangana), highlighting SUVENPHA’s focus on innovation-led growth.

Evolving into CDMO powerhouse: SUVENPHA has transformed since its founding in 1989, evolving from a generic active pharmaceutical ingredients (API) player to a complex chemicals and CDMO services company. The turning point came in CY20 when it was spun off from Suven Life Sciences to focus on CDMO while its parent, shifted focus to central nervous system (CNS) disorder research. While organic growth continued, in CY22 Advent International acquired a 50.1% stake in the company and merged it with Cohance Lifesciences. SUVENPHA expanded its capabilities by investing in Sapala Organics in June 2024 and bought NJ Bio for USD 64.4mn in December 2024, strengthening its presence in the ADC & X-drug conjugates (XDC) and reinforcing its position in global drug development.

Commercial ADC sales expected to reach ~USD 50bn by CY30: The acquisition of NJ Bio marks SUVENPHA’s entry into the fast-growing ADC market, a field that has expanded with 15 approved drugs and multi-billion-dollar sales. As research shifts towards combination therapies to enhance effectiveness and reduce resistance, clinical trials have surged, reaching 816 by mid-CY24, with many paired with immune checkpoint inhibitors. With four ADC combination therapies already approved, the company is well-positioned to contribute to this evolving landscape and play a key role in the future of cancer treatment.

Strong R&D capability with product-led CDMO: Driven by innovation and a robust R&D foundation, the company has modernized its facilities with advanced equipments and a new campus at Genome Valley. Equipped for both pilot- and full-scale commercial manufacturing, it efficiently handles complex chemistry while ensuring scalability for future growth. With a primary focus on small molecules, SUVENPHA supports global pharmaceutical innovators through clinical phases of drug development, playing a crucial role in advancing breakthrough therapies.

Guidance of sales of USD 1bn by FY30: SUVENPHA aims to reach USD 1.0bn in sales by FY30, with 80% contribution from CDMO. This growth will be fueled by expansion across segments, particularly in ADC, adoption of differentiated modalities such as oligonucleotides and Horizon 2 technologies, supported by strategic acquisition to enhance specialized capabilities, such as peptides. SUVENPHA’s strong leadership team includes CXO advisors from leading global companies such as Lonza, Catalent, and Patheon

Please refer disclaimer at Report
SEBI Registration number is INH000000933